Biological context
Esophageal cancer is one of the most common fetal cancers worldwide and occurs at very high frequencies in developing countries (Parkin et al. 1993) . Esophageal cancerrelated gene 2 (ECRG2), also named serine peptidase inhibitor Kazal-type 7 (SPINK7), was identified as a growth-regulating gene by comparing normal esophageal epithelia and primary squamous cell carcinomas tissues from high incidence families in Lin-Xian County of China using differentially displayed PCR (Su et al. 1998; Cui et al. 2010) . It has been shown that ECRG2 is a tumor suppressor gene involved in the regulation of cell proliferation, induction of apoptosis, and inhibition of cancer cell migration, invasion and metastasis (Cui et al. 2003; Huang et al. 2007 ). ECRG2 also participates in centrosome amplification in a p53-dependent manner and has a role in maintaining chromosome stability (Cheng et al. 2008) . Recently, it was found that ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator (uPA)/urokinase-type plasmin activator receptor (uPAR) pathway by directly inhibiting uPA/plasmin activity, and may represent a novel therapeutic target for cancer (Huang et al. 2007; Cheng et al. 2009 Cheng et al. , 2010 Cui et al. 2010) .
The full length ECRG2 protein contains 85 residues, in which the N-terminal 19 residues form a signal peptide and the C-terminal 56 residues (residues 30-85) contain a typical . The Kazal-type protease inhibitors with various physiological functions are conserved across species ranging from human to invertebrates (Laskowski and Kato 1980; Rimphanitchayakit and Tassanakajon 2010) while ECRG2 is classified as a serine peptidase inhibitor Kazal-type 7 and conserved in mammalians (Fig. 1) . Moreover, the Kazal-type protease inhibitors have a scissile peptide bond that is potentially cleaved by the protease with a very low reaction rate (Laskowski and Kato 1980; Rimphanitchayakit and Tassanakajon 2010) . The scissile peptide bond of ECRG2 is between P1 residue (Ile47) and P 0 1 residue (Thr48) (In inhibitors, the number after ''P'' indicates the position of the residue towards the N-terminus of the scissile bond, while after ''P 0 '' indicates residues towards the C-terminus of the scissile bond). In addition, ECRG2 contains more residues between the first two cysteines besides its N-terminal signal peptide as compared with the other Kazal-type protease inhibitors (Geng et al. 2008) .
The backbone and partial side chain resonance assignments for ECRG2 were determined previously by NMR technique (Geng et al. 2008) . Utilizing a homology modeling and the NMR titration experiments, a putative reactive site of ECRG2 as the uPA-binding site was identified, suggesting that ECRG2 can inhibit uPA activity through a manner similar to the other Kazal-type inhibitors of serine proteases (Geng et al. 2008) . In the present study, the complete NMR resonance assignments of ECRG2 were The scissile peptide bond on the reactive loop is indicated by an arrow. P1, P2, etc. denote the residues towards the N-terminus of the scissile peptide bond, while P 0 1, P 0 2, etc. denote the residues towards the C-terminus of the scissile peptide bond. The residues in a-helices and b-strands are in red and cyan, respectively. d Structure superimposition of ECRG2 (red) and ovomucoid (green). e Structure superimposition of ECRG2 (red) and PSTI (blue). f Structure-based sequence alignment of ECRG2, ovomucoid, and PSTI. Disulfide bonds are indicated by lines. The secondary structural elements of ECRG2 are indicated at the top of sequences obtained, and the high quality solution structure of ECRG2 was determined by NMR spectroscopy. Analysis of the ECRG2 structure revealed a number of structural features distinct from the other Kazal-type protease inhibitors, which suggest ECRG2 to be an interesting specific inhibitor of uPA activity.
Methods and results

Protein expression and purification
Since the N-terminal 19 residues of ECRG2 form a signal peptide, these 19 amino acids were truncated in construction of the expression vector for obtaining the recombinant ECRG2 protein. The peptide ECRG2(20-85) (called as ECRG2 hereafter for simplicity) were expressed and purified as described previously (Geng et al. 2008 C NOESY-HSQC were adopted for the backbone and side chain resonance assignments. The mixing times for 13 C-13 C TOCSY and 1 H-1 H NOESY experiments were 12 and 200 ms, respectively. All NMR data were processed and analyzed with FELIX software (Accelrys Inc.).
Structure calculation
Initial structures of ECRG2 were generated using the CANDID module of the CYANA software (Herrmann et al. 2002) , and the NOE assignments given by CANDID were checked manually. The structures were refined in explicit water using CNS software (Brunger et al. 1998) and RECOORDScript (Nederveen et al. 2005) . The dihedral restraints generated using TALOS? (Cornilescu et al. 1999; Shen et al. 2009 ) and the disulfide bonds C32-C67, C45-C64, and C53-C85 were introduced in the structure refinements. 100 structures were calculated, and 20 structures with lowest energies were selected for final analysis. The quality of the structures was analyzed using MOLMOL (Koradi et al. 1996) and PROCHECK-NMR (Laskowski et al. 1996) . All figures depicting structures were generated using MOLMOL. The Dali server (Holm and Rosenstrom 2010) and SSM server (Krissinel and Henrick 2004) were utilized for searching the structural similarity.
Structure of ECRG2
ECRG2 belongs to the Kazal-type protease inhibitor which contains six conserved cysteine residues forming three intra-molecular disulfide bonds between pair wise cysteine residues Cys32-Cys67, Cys45-Cys64, and Cys53-Cys85. The correct formation of these disulfide bonds in recombinant ECRG2 is crucial for further structural and functional studies of this protein. The obtained chemical shifts and NOE patterns in our previous study suggested that the purified ECRG2 contained three correctly formed disulfide bonds (Geng et al. 2008) , and this was further confirmed by the structural determination in the present study.
The initial structures of ECRG2 were calculated with the chemical shift assignments and NOE data by an automatic method using the software CYANA. No disulfide bond restraints were used for the initial structure calculation. The structures generated by CYANA showed a Kazal fold with six correctly paired cysteine residues as they should be in a Kazal fold (data not shown). Since the initial structure calculation was performed without the disulfide bond restraints or manual NOE assignments, the obtained initial structures proved the correct folding and oxidation of the purified recombinant ECRG2 proteins. Therefore, the disulfide bond restraints were added in the subsequent structure calculations.
The solution structures of ECRG2 were then determined with NOE-derived distance, backbone dihedral angle, hydrogen bond, and disulfide bond restraints (Table 1) . Residues 29-85 of ECRG2 form a compact core structure while the N-terminal region (20-28) is disordered (Fig. 2) . The core structure contains two a-helices (a1: 33-36 and a2: 63-72), an anti-parallel b-sheet formed by three bstrands (b1: 52-54, b2: 59-60, and b3:79-82), and four loops connecting the secondary structural elements: L a1b1 (37-51), L b1b2 (55-58), L b2a2 (60-62), and L a2b3 (73-79) (Fig. 2) . The three disulfide bonds, C32-C67, C45-C64, and C53-C85 are established between the N-terminus of helix a1 and helix a2, between middle of loop L a1b1 and helix a2, and between strand b1 and the C-terminus of the protein, respectively. No large hydrophobic core is formed except four small hydrophobic regions (Val52-Tyr60-Leu66-Val77-Phe79, Ile34-Tyr35-Tyr38-Pro44, Pro46-Thr48-Leu50, and Lys36-Val40-Leu71) in the ECRG2 structure. These hydrophobic residues and three disulfide bonds were the key factors contributing to the stability of the structure.
Deposition of assignments and structure coordinates
The atomic coordinates and NMR-derived restraints of ECRG2 have been deposited in the Protein Data Bank (http://www.rcsb.org/) with accession code 2LEO. The chemical shift assignments of ECRG2 have been deposited in the Biological Magnetic Resonance Data Bank (http:// www.bmrb.wisc.edu/) with accession number 17719.
Discussion and conclusions
ECRG2 is a Kazal-type inhibitor with distinct structural features
The structural homology search in PDB using the Dali server and the SSM server found a Kazal-type inhibitor fold of the ECRG2 structure and a large number of Kazal domain structures similar to that of ECRG2. The high structural similarity was identified for ECRG2 with ovomucoid and human pancreatic secretory trypsin inhibitor (PSTI) (PDB codes 2OVO and 1HPT) (Fig. 2d, e) , providing the highest DALI Z scores of 8.0 and 6.3, and the RMSDs of 1.9 and 2.6 Å , respectively.
However, careful analysis revealed several significant differences between structures of ECRG2 and other Kazal domains. The first major difference was shown by the backbone and secondary structure in the segment between the first two cysteine residues. The residues in this segment are not conserved in Kazal domains and the conformation of this segment in ECRG2 is quite different from that in other Kazal domains. An additional short helix was formed by the residues in this segment of ECRG2 (Fig. 2d-f) . Second, the reactive site is more hydrophobic in ECRG2 than in other Kazal domains. The ECRG2 reactive site loop, residues from P4 to P 0 4 positions (PCPITYLP), contains five hydrophobic but no charged residues. However, Ovomucoid and PSTI contain two or three hydrophobic and one to three charged residues. Third, ECRG2 has more solvent exposed hydrophobic residues (Ile, Leu, Val, Pro, Phe) except those in the reactive site loop. ECRG2 contains 9 solvent-exposed hydrophobic residues in a total of 66 residues, but ovomucoid and PSTI contain only 2 and 5 solvent-exposed hydrophobic residues in a total of 56 residues, respectively (Fig. 3a, c, e) . Fourth, the electrostatic potential surface of ECRG2 is quite different from ovomucoid and PSTI (Fig. 3b, d, f) . On the surface of ECRG2, there are more neutral and negatively charged residues around the reactive loop, and positively charged residues on the opposite side. However, more positively charged residues are around the reactive site of Ovomucoid and PSTI.
The distinct structure features of ECRG2 revealed in this study suggest that ECRG2 may have unique functions different from other Kazal-type inhibitors. The determined solution structure here could provide a structural basis of ECRG2-based drug development since the function of ECRG2 as an uPA inhibitor makes it to be a potential drug. However, the complicated purification procedure and poor long-term stability of ECRG2 become the shortcomings in dealing with ECRG2. To overcome these shortcomings needs the further engineering studies based on the determined ECRG2 structure. Conclusions ECRG2 is a Kazal-type inhibitor with distinct structural features. The determined ECRG2 structure has an additional short a-helix, hydrophobic reactive site, more solvent-exposed hydrophobic residues, and unique surface charge distribution, showing a unique structure different from the known Kazal-type inhibitors. These imply that ECRG2 may have a specific inhibitor activity which may be an attractive feature for uPA inhibitors in the future discovering of the potential cancer therapy.
